

## ORTAC Symposium 2020: Building Bridges in Community Health

University of Pittsburgh, School of Pharmacy  
Program Evaluation and Research Unit (PERU)

**Location:** Virtual Symposium hosted on Zoom Webinar

**Date:** Tuesday, 9/22/2020 and Wednesday, 9/23/2020

### Program Overview

Treatment and the engagement/retention for patients with a substance use disorder is under significant demand. A key aspect of successful engagement with the substance use population is to "meet the patient where they are," which can assume a variety of forms. This symposium will address the unique "bridges" that are essential to provide comprehensive care for individuals with a substance use disorder, primarily individuals with an opioid use disorder. Innovative programs to "meet the patient where they are" will be discussed, as well as ways to utilize an integrative approach when working with a patient in this population. Gaps remain in the awareness of effective initiatives to reach this population and enhance their quality of care.

### Learning Objectives:

1. Understand the importance of integrating physical, mental and behavioral health.
2. Identify how first responders can effectively bridge areas of need in the community.
3. Describe the use of a telemedicine bridge program for medications for opioid use disorder.
4. Examine the impact of substance use disorders on family/friends of individuals with a substance use disorder.

### Target Audience:

Pharmacist, Physician, Physician Assistant, Psychologist, and Social Worker.

### Faculty Listing

- Patricia Kroboth, PhD  
Dean of University of Pittsburgh School of Pharmacy  
Dr. Gordon J. Vanscoy Professor of Pharmaceutical Sciences  
Pittsburgh, PA
- James Schuster, MD  
VP of Behavioral Integration and the Chief Medical Officer for Behavioral, Medicaid and Special Needs Services for the UPMC Insurance Division  
Pittsburgh, PA
- Colleen Hughes, MS, CAAD  
Executive Director of the Westmoreland Drug & Alcohol Commission  
Monessen, PA
- Amanda Mihalko, MS  
Program Director, Community Health Initiatives, University of Pittsburgh, School of Pharmacy,  
Program Evaluation and Research Unit  
Pittsburgh, PA
- Michael Lynch, MD

Medical Director, Pittsburgh Poison Center  
 Medical Director, UPMC Health Plan Substance Use Services  
 Pittsburgh, PA

- Crystal Parish, LPC  
 Vice President of Clinical Operations, LaurelCare Treatment  
 Kennedy Twp, PA

<b>2020 AGENDA</b>	<b>“Building Bridges: Community Partnerships to Mitigate Opioid Overdoses”</b>
--------------------	--

Day 1—September 22nd, 2020

Time	Session Title and Description
8:45-8:55	<p><b>Welcome and Introduction</b></p> <p><b>Patricia Kroboth, PhD</b> – Dean of University of Pittsburgh School of Pharmacy and the Dr. Gordon J.Vanscoy Professor of Pharmaceutical Sciences</p>
9:00-10:15	<p><b>Presentation 1: Integration of Physical, Mental, and Behavioral Health</b>            Enhancing Wellness in Individuals with Substance Use Disorders</p> <p><b>James Schuster, MD</b>, VP of Behavioral Integration and the Chief Medical Officer for Behavioral, Medicaid and Special Needs Services for the UPMC Insurance Division</p>
10:15-10:30	Break
10:30-11:45	<p><b>Presentation 2: Bridging Gaps, Public Health and Public Safety</b></p> <p>Expanding the Role of First Responders</p> <p><b>Colleen Hughes, M.S.</b>, CAAD, Executive Director of the Westmoreland Drug &amp; Alcohol Commission</p>
11:45-12:00	Closing Remarks

## 2020 AGENDA

**“Building Bridges: Community Partnerships to Mitigate Opioid Overdoses”**

Day 2—September 23rd, 2020

Time	Session Title and Description
	<b>Welcome and Introduction</b>
12:45 – 12:55	<b>Amanda Mihalko, MS</b> – Program Director, Community Health Initiatives University of Pittsburgh, School of Pharmacy, Program Evaluation and Research Unit
	<b>Presentation 1: Building Access to MOUD</b>
12:55 – 2:15	UPMC Medical Toxicology Telemedicine Bridge Program <b>Michael Lynch, MD</b> , Medical Director – Pittsburgh Poison Center, Medical Director – UPMC Health Plan Substance Use Services
	Break
2:15 – 2:30	
	<b>Presentation 2: Impact on Families</b>
2:30 – 3:45	Addiction in the Family: Empowering Family Members to Become Change Agents in the Recovery Process <b>Crystal Parish, LPC</b> , Vice President of Clinical Operations – LaurelCare Treatment
3:45 – 4:00	Closing Remarks

## **Accreditation and Designation**

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Physician (CME)**

The University of Pittsburgh designates this live activity for a maximum of 5.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Nursing (CNE)**

The maximum number of hours awarded for this Continuing Nursing Education activity is 5.25 contact hours.

### **Pharmacy (CPE)**

This knowledge-based activity provides 5.25 contact hours of continuing pharmacy education credit.

### **Other Healthcare Professionals**

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

## **Disclaimer**

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

## **Faculty Disclosure**

All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

The following relevant financial relationships were disclosed:

Julie A. Kmiec, DO – SAMHSA and AHRQ grant recipient

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.